CA2486043C - Method for determining an analyte by means of an extraction layer - Google Patents

Method for determining an analyte by means of an extraction layer Download PDF

Info

Publication number
CA2486043C
CA2486043C CA2486043A CA2486043A CA2486043C CA 2486043 C CA2486043 C CA 2486043C CA 2486043 A CA2486043 A CA 2486043A CA 2486043 A CA2486043 A CA 2486043A CA 2486043 C CA2486043 C CA 2486043C
Authority
CA
Canada
Prior art keywords
compartment
substance
indicator substance
sample
indicator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2486043A
Other languages
French (fr)
Other versions
CA2486043A1 (en
Inventor
Joachim Hoenes
Christine Nortmeyer
Carina Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2486043A1 publication Critical patent/CA2486043A1/en
Application granted granted Critical
Publication of CA2486043C publication Critical patent/CA2486043C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/525Multi-layer analytical elements
    • G01N33/526Multi-layer analytical elements the element being adapted for a specific analyte
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721Haemoglobin
    • G01N33/723Glycosylated haemoglobin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention concerns a method for determining an analyte in a liquid sample by means of a test system consisting of at least two compartments wherein the detection reactions necessary to determine the analyte in the liquid sample are carried out in a first compartment and an analytical determination of at least one substance which participates in the detection reactions and is different from the analyte, the indicator substance, takes place in a second compartment characterized in that the two compartments are separated in a manner which allows the indicator substance to pass into the second compartment and at least partially prevents passage of other substances that could interfere with the analytical determination of the indicator substance in the second compartment and that at least one other substance which, as a capture substance, can selectively enrich the indicator substance in the second compartment, is present in an immobilized form in the second compartment. Other subject matters of the invention are test systems for carrying out such methods and the use of these test systems for the determination of analytes according to the invention.

Description

Method for determining an analyte by means of an extraction layer Description The application concerns a method for determining analytes in a liquid sample which allows an analyte determination with high specificity and sensitivity especially when other substances are present in the liquid sample which interfere with the determination of the analyte. The application also concerns a test system for determining analytes in a liquid sample corresponding to the method according to the invention as well as its use according to the invention.

State of the art The analytical detection and determination of the concentration of certain biological and medically relevant substances, so-called analytes, in complex samples is an important basis of modern medical diagnostics.

So-called carrier-bound tests are often used for the qualitative and quantitative determination of analytes in liquid samples, in particular in blood or urine.
In these dry chemistry methods the reagents are present in a dry form on or in appropriate layers of a solid test carrier which is contacted with the sample. The reaction of liquid sample and reagents results in a detectable signal, especially a change in colour or fluorescence which can be evaluated visually or with the aid of an instrument, usually by means of reflection photometry or fluorimetry. Other detection methods are based on electrochemical methods and for example detect changes in charge, potential or current. Such test carriers are often formed as test strips which are essentially composed of an elongate carrier layer, a detection layer containing the detection reagents and possibly other auxiliary layers, for example filtration layers.

A major problem of these analytical methods is that in many cases the analyte cannot be directly detected in complex sample mixtures since other substances present in the sample liquid apart from the analyte influence or even completely prevent the analyte determination. In such cases a prior separation of the analyte from these interfering substances is necessary in previous methods in order to be able to carry out a specific and sensitive analyte determination at all. Such purification steps prior to the actual analyze determination often require additional steps in the procedure such as washing steps, precipitation reactions, centrifugation steps, adsorption steps, phase separations or filtrations and hence such methods are often very time consuming, laborious and require complicated apparatus. Thus in order to simplify the analysis and make it more economical it is desirable to avoid such additional purification steps. Another disadvantage of purification steps is that they change the composition of the sample liquid. As a result it is no longer possible to ensure that the analyte is determined in the native reaction environment especially in the case of complex detection reactions involving several reaction steps and reaction partners, for example enzymatic reaction cascades such as blood coagulation, thus falsifying the analyte determination or making it impossible.

In layered test systems a wide variety of blood parameters are often detected by specific enzymatic detection reactions and subsequent detection of a product formed in this process, the so-called indicator substance. However, a prerequisite for this is that the properties of the sample liquid and in particular the presence of other substances in the same sample do not influence the detection of the indicator substance. Thus a determination of an analyte in blood by optical methods can often not be carried out without a complex pretreatment of the sample since the haemoglobin that is present in a high concentration in blood makes it impossible to optically determine analytes at low concentrations due to its optical properties.
Therefore in these cases a separation of these substances or cells is usually unavoidable in the previously used methods.

A problem which frequently occurs when detecting analytes especially by means of enzymatic reactions is that such reaction mixtures often have a very complex composition which, on the one hand, results in a low stability and high susceptibility to interference of the detection reaction. On the other hand, many substances some of which are present at extremely low concentrations in the reaction mixture or whose occurrence or significance is still unknown, are often necessary to allow the detection reaction to occur in an environment which resembles the native environment as closely as possible. An example of this is the coagulation reaction.

_3_ However, this complex composition is disadvantageous for the detection of the indicator substance in this reaction mixture which is converted during the course of the detection reactions since various interactions can occur between substances present in the sample or in the detection reagent mixture which in turn can have a major effect on the determination of the indicator substance. In each case complicated measures are necessary to separate such interfering components of the liquid sample in order to prevent them from interfering with or preventing the determination of the indicator substance. Especially when determining analytes in whole blood, this means that an additional plasma separation is thus often unavoidable.

An example of this is the determination of blood sugar in whole blood by photometric methods which are based on the principle of an enzymatic conversion of glucose especially by glucose oxidase or glucose dehydrogenase as part of a colour generating reaction. In this case, blood cells and especially the red blood corpuscles have to be removed by filtration on the surface of the detection layer so that only an almost colourless plasma can penetrate into the detection layer. The colour generating reaction then takes place in this layer which can be measured photometrically. However, this requires that the red blood corpuscles are reliably separated and that their red colour is held back from the detection layer by additional colour pigments.

Glass fibre fleeces as for example described in EP 0045476 can for example be used for this purpose. These glass fibre fleeces already separate interfering components and in particular erythrocytes before the detection reactions begin. The operating principle is based on filtration and chromatographic effects.

Another example is the determination of blood coagulation parameters that are based on the conversion of a fluorescent thrombin substrate. Also in this case it is necessary to remove interfering components of the sample liquid and especially the strongly absorbing haemoglobin. Such methods are for example used in the Avocet system to determine coagulation parameters (Avocet Medical Inc., San Jose, CA, USA). In this case the red blood corpuscles and haemoglobin are separated by a membrane while plasma can pass through the membrane and the detection reaction for determining thrombin can take place in the underlying layers. In the course of this reaction a fluorescent particle is formed in these layers which reflects the time course of blood coagulation. The measurement cannot be carried out in blood itself since blood would completely suppress the fluorescence. Also in this case the interfering components are already separated from the sample liquid before the start of the actual detection reaction.

EP 0974303 describes a blood sugar measuring instrument for determining the blood sugar level based on a colour change in a sample in which the reagent layer section comprises the actual reagent layer which is coloured by the reaction with blood and a filter layer for filtering the blood cells. In this case the determination of blood sugar takes place by applying a drop of blood to an application opening which subsequently reaches the reagent layer where the detection reaction occurs and in the course of which there is a change in the colour of the sample liquid. Subsequently the sample liquid migrates further into the filter layer in which blood cells are filtered out. The reflection-photometric detection of the colour change of the sample also takes place in the filter layer. EP 0974303 uses especially a fine-pored polyethersulfone film having pore sizes of 0.45 m as a filter layer to separate blood cells. In this case undesired components are separated by purely physical methods i.e. undesired substances are kept out of the filter layer by the principle of size exclusion. A
disadvantage of such fine-pored filtration methods is that the pores of such filter layers can easily become blocked. Thus, especially in the case of high concentrations of particles in the sample such as is the case in whole blood, the filter layer can rapidly become blocked which greatly impairs the detection of the indicator substance since an increasing blockage of the pores reduces the amount that can penetrate into the detection layer. Hence a consequence of such methods can be concentration values that are too low and poor reproducibility, especially depending on the original sample.

In "The Use of Fluorogenic Substances to Monitor Thrombin Generation for the Analysis of Plasma and Whole Blood Coagulation" (Analytical Biochemistry 277, 18 (2000)) Ramjee describes methods for the fluorimetric determination of thrombin using fluorescent thrombin substrates that can be carried out directly without separating interfering components of the sample liquid. Sample materials that can be used in these methods are redissolved, lyophilized, fibrin-containing plasma, fresh thrombocyte-depleted plasma, thrombocyte-containing plasma and whole blood.
The thrombin is detected by converting a weakly fluorescent thrombin substrate into a strongly fluorescent reaction product which can be detected directly in the sample solution as an indicator substance. In this case there is no separation of interfering sample components which means that both the detection reactions and the determination of the indicator substance occur in the same compartment i.e. in this case directly in the sample liquid. This thrombin detection is only described as a liquid test and not on a dry chemistry basis. However, these test systems show that it is only possible to a very limited extent to determine thrombin in whole blood. When using whole blood as the sample liquid, the fluorescence signal intensity is reduced to less than one tenth of the plasma value in comparison to plasma. Hence it is not possible to carry out analytical determinations with a high sensitivity in whole blood using these methods. This strong reduction of the measured fluorescence intensity in whole blood is due to an absorption of the excitation and fluorescence light by chromogenic substances in blood and especially by haemoglobin which is present in the same compartment as the indicator particles. Hence in order to increase the sensitivity it would be additionally necessary to separate the interfering substances for example by filtration or centrifugation which is associated with the previously described disadvantages.

German published patent application number DE 10221846.3 describes a method for detecting an analyte in a sample by an enzymatic reaction by contacting the sample with a detection reagent which contains a coenzyme and a catalytically inactive coenzyme-binding protein. According to the invention the coenzyme is changed by the reaction with the analyte and binds in its changed form to the catalytically inactive coenzyme-binding protein. The detection of the changed coenzyme is used for the analyte determination. In this case the catalytically inactive coenzyme-binding protein at least partially has the function of a capture substance by binding the changed coenzyme without converting it further. In this case the capture substance is added to the other detection reagents. In a special embodiment the entire detection reaction is incorporated into a matrix such that the capture substance and the other detection reagents are located in a common layer.

Object of the invention:

The object of the present invention is to at least partially avoid the described disadvantages of the prior art. In particular it is intended to provide a method for detecting analytes which enables a sensitive and specific determination of analytes even in complex sample liquids and satisfies the requirements of an economical and user-friendly routine analysis.

In accordance with one aspect of the invention, there is provided a method for determining a coagulation parameter in a sample of whole blood or a blood product derived therefrom, comprising:
a) providing a test system having at least two compartments, comprising a first compartment for a detection reaction required to determine said coagulation parameter, the detection reaction producing an indicator substance, and a second compartment for an analytical determination of the indicator substance, said first compartment being separated from said second compartment in a manner which allows the indicator substance to pass from the first compartment into the second compartment, while at least partially preventing passage of interfering components of the sample, which components can interfere with the analytical determination of the indicator substance in the second compartment; and a specific capture substance which selectively enriches the indicator substance in the second compartment being present in an immobilized form in the second compartment;
b) carrying out the detection reaction in said first compartment with conversion of a fluorescently labelled thrombin substrate to form a fluorescent indicator substance;
c) allowing the fluorescent indicator substance to pass into said second compartment and be enriched by said immobilized specific capture substance, without interfering components of the sample; and d) optically detecting the fluorescent indicator substance in the second compartment.

In accordance with another aspect of the invention, there is provided a method for determining glycosylated haemoglobin in a sample of whole blood or a blood product derived therefrom, comprising:

-6a-a) providing a test system having at least two compartments, comprising a first compartment for a detection reaction required to determine said glycosylated haemoglobin, and a second compartment for an analytical determination of an indicator substance present in said first compartment, said first compartment being separated from said second compartment in a manner which allows the indicator substance to pass from the first compartment into the second compartment, while at least partially preventing passage of interfering components of the sample, which components can interfere with the analytical determination of the indicator substance in the second compartment; and a specific capture substance which selectively enriches the indicator substance in the second compartment being present in an immobilized form in the second compartment;
b) specifically binding glycosylated haemoglobin with a low molecular weight labelled reagent in said detection reaction in said first compartment to produce glycosylated haemoglobin bound labelled reagent and unbound labelled reagent in said first compartment, said unbound labelled reagent being said indicator substance for said analytical determination in the second compartment;
c) allowing said unbound labelled reagent, as indicator substance, to pass into said second compartment and be enriched by said immobilized specific capture substance, while leaving interfering components of the sample and glycosylated haemoglobin bound labelled reagent in said first compartment; and d) optically detecting the indicator substance in the second compartment.
In still another aspect of the invention, there is provided a test system for determining a coagulation parameter in a sample of whole blood or a blood product derived therefrom, comprising at least two compartments comprising a first compartment for carrying out a detection reaction required to determine the coagulation parameter and a second compartment for an analytical determination of an indicator substance which participates in the detection reaction, wherein:
a) the first compartment and the second compartment are separated from one another in a manner which allows the indicator substance to pass from the first compartment into the second compartment, while at least partially preventing passage of interfering components of the sample, which components can interfere with the analytical determination of the indicator substance in the second compartment;

- 6b -b) a specific capture substance immobilized in the second compartment, said specific capture substance selectively enriching the indicator substance in the second compartment; and c) the indicator substance is a fluorescent indicator substance formed in said first compartment by conversion of a fluorescently labelled thrombin substrate.

In yet another aspect of the invention, there is provided a test system for determining glycosylated haemoglobin in a sample of whole blood or a blood product derived therefrom, comprising at least two compartments comprising a first compartment for carrying out a detection reaction required to determine the glycosylated haemoglobin and a second compartment for an analytical determination of an indicator substance which participates in the detection reaction, wherein:
a) the first compartment and the second compartment are separated from one another in a manner which allows the indicator substance to pass from the first compartment into the second compartment, while at least partially preventing passage of interfering components of the sample, which components can interfere with the analytical determination of the indicator substance in the second compartment;
b) the indicator substance, in the first compartment, which participates in the detection reaction, is a low molecular weight labelled reagent which specifically binds to glycosylated haemoglobin in said first compartment to produce glycosylated haemoglobin bound labelled reagent and unbound labelled reagent in said first compartment, said unbound labelled reagent being said indicator substance for said analytical determination in the second compartment; and c) a specific capture substance is immobilized in the second compartment to selectively enrich the indicator substance, from the first compartment, in the second compartment.

-6c-Solution according to the invention:

This object is achieved according to the invention by adding an additional extraction layer to the components of a test system described in the prior art. This additional extraction layer allows the indicator substance used for the analyte determination to be selectively enriched in regions of the test system in which the analytical detection of this indicator substance takes place. The extraction layer according to the invention additionally enables substances to be held back which could interfere with the determination of the indicator substance in the detection layer.
Especially in the case of analytes present in blood, the detection reactions for determining the analyte could thus actually take place in whole blood while the indicator particles participating in these reactions are subsequently selectively enriched from this blood compartment in the extraction layer and can then be detected in this layer substantially free of interference. This allows an exact and sensitive' determination of analytes in a single test system even without additional separation steps.

Hence one subject mater of the invention is a method for. determining analytes in a liquid sample by means of a test system consisting of at least two compartments wherein the detection reactions necessary to determine the analyte in the liquid sample are carried out in a first compartment, i.e. the reaction space, and the analytical determination of at least one substance involved in the detection reactions, i.e. the indicator substance, takes place in a second compartment, i.e. the extraction layer. Such a test system according to the invention is characterized in that the two compartments are separated in a manner which allows the indicator substance to pass into the extraction layer and other substances that could interfere with an analytical determination of the indicator substance are at least partially prevented from passing into the extraction layer. Furthermore the test system according to the invention is characterized in that at least one other substance that selectively enriches the indicator substance is present as capture substance in the extraction layer in an immobilized form.

Another subject matter of the present invention is a test system for determining analytes in a liquid sample which consists of at least two spatially separate compartments wherein the detection reactions especially involving the indicator substance that are necessary to determine the analyte in the liquid sample are carried out in a first compartment, the reaction space and the analytical determination of the indicator substance is carried out in a second compartment, the extraction layer. In order to increase the specificity and sensitivity, the extraction layer additionally contains, according to the invention, a capture substance in an immobilized form which selectively enriches the indicator substance. According to the invention these two compartments are spatially separated in such a manner that in particular passage of the indicator substance into the extraction layer is favoured but, on the other hand, substances which could interfere there with an analytical determination of the indicator substance are at least partially excluded from this layer.

Another subject matter of the invention is the use of a test system according to the invention to determine analytes in a liquid.

The principle of operation of the test system according to the invention can be described as follows:

The determination of the analyte does not occur directly but is rather mediated by an indicator substance which is converted or formed during the course of analyte-specific detection reactions. These detection reactions occur directly in the sample liquid after addition or release of the required detection reagents, preferably without an additional sample preparation. The concentration of an indicator substance is changed in this process either directly from the analyte to be determined or via a more complex chain of reactions which involve the analyte. This indicator substance has a low molecular weight and is in an equilibrium distribution between the reaction space and the extraction layer which establishes in particular as a result of diffusion.

Capture substances immobilized in the extraction layer selectively enrich the indicator substance in the extraction layer and thus considerably increase the sensitivity of the analyte determination. Hence analytes which cannot themselves enter into the extraction layer can be determined with high sensitivity. On the other hand, other sample components which could interfere with the determination of the indicator substance such as the strongly absorbing haemoglobin, are substantially excluded from the extraction layer.

The test systems and methods according to the invention can, however, also be used for electrochemical detection methods in which the presence of complex sample mixtures is not such a major problem due to the method of measurement. The enrichment of the indicator substances in the extraction layer as a result of the capture substances that are immobilized there increase the measurement signal which can increase the sensitivity and specificity of the analytical determination.

Test systems in the sense of the present application are all devices which allow a determination of an analyte in a liquid sample. Such test systems preferably have a carrier-bound structure. Such test carriers are often in the form of test strips which essentially consist of an elongate support layer made of plastic material and detection elements mounted thereon as test fields. However, test carriers are known which are in the form of small square or rectangular plates. A particularly preferred embodiment consists of an inert base support on which an extraction layer according to the invention is mounted and which additionally has a reaction space in which the detection reactions involving the analyte and the indicator substance take place and which thus contains the substances required for the detection reactions. This reaction space can be present as a special layer of the test system or also be formed by the liquid sample itself. In the latter case the detection reagents can be present in a dry form on the test carrier, especially on or within the extraction layer and are not dissolved and released into the reaction space until the liquid sample is applied which starts the detection reactions in the reaction space. Furthermore, the required detection reagents can be added to the liquid sample in a prior step and subsequently this reaction mixture is applied to the test carrier and in particular to the extraction layer.

Analytes which can be determined using a method according to the invention or the corresponding devices are, in the sense of the present application, all particles which are of interest in analytics especially in clinical diagnostics. In particular the term "analyte" encompasses atoms, ions, molecules and macromolecules, in particular biological macromolecules such as nucleic acids, peptides and proteins, lipids, metabolites, cells and cell fragments. Analytes which occur in whole blood and are detected by means of detection reactions which require other substances present in whole blood can be determined particularly advantageously using the methods and test systems according to the invention. Examples of this are analytes involved in blood coagulation such as thrombin or factor Xa which for their determination require other essential substances in the coagulation cascade that are present in whole blood and are often macromolecular and therefore such an analyte determination has to be carried out in whole blood.

Other preferred analytes are enzymes or enzyme substrates. Enzymatic analytes may in particular be hydrolases such as peptidases, esterase, glycosidases, phosphatases and sulfatases. Substrates of these enzymes, in particular natural substrates can also be determined. Competition of the natural substrate with an artificially labelled substrate analogue can be utilized for this purpose. Cleavage of the indicator substances from artificially labelled substrates is lower in the presence of the natural substrates since the cleaving enzyme can in each case only cleave one of the two. This effect can be used to determine the amount of the natural substrates.

Glucose and glycosylated haemoglobin can also be determined as another preferred analyte. In this case especially the release of phenylenediamine can be utilized which is an intermediate product of many photometric and electrochemical glucose tests.
This phenylenediamine can be used as an indicator substance and for example be concentrated in the extraction layer by cyclodextrins which increases the sensitivity of the detection methods and can avoid the risk of bleeding in the sample.

Other preferred analytes may be partners of a specific binding pair. If molecules which bind specifically are allowed to interact with their labelled binding partners in the reaction space and a specific capture substance for the same labelled partner is provided in the extraction layer, an equilibrium distribution establishes between the reaction space and extraction layer such that the more labelled binding partner is present in the layer, the less labelled binding partner is specifically bound in the sample liquid of the reaction space. In this case the label must be selected such that it is suitable for the measurement method and has an adequate affinity for the capture substance. Examples of this are labelled haptens and the specific antibody, labelled cofactors and enzymes or labelled complementary nucleic acids. Also other binding partners such as biotin/streptavidin or biotin/avidin can be used in this case.

Liquids in the sense of the present invention maybe pure liquids and homogeneous or heterogeneous mixtures such as dispersions, emulsions or suspensions. In particular atoms, ions, molecules and macromolecules, in particular biological macromolecules such as nucleic acids, peptides and proteins, lipids, metabolites and also biological cells or cell fragments may be present in the liquids.
Preferred liquids of biological origin to be examined are blood, plasma, serum, urine, cerebrospinal fluid, lachrymal fluid, cell suspensions, cell supernatants, cell extracts, tissue lysates etc.. Liquids may, however, also be calibrator solutions, reference solutions, reagent solutions or solutions containing standardized analyte concentrations, so-called standards.

In the present invention the determination or detection of substances means a qualitative as well as a quantitative detection of substances. In particular it is understood as a determination of the concentration or amount of the respective substance, ascertaining the absence or presence of a substance being also regarded as a determination of the substance.

Analytes are determined using specific detection reactions in a known manner in analytics. The analyte to be determined is not detected directly but rather the analyte to be determined participates in one or more detection reactions in the course of which the indicator substance that is different from the analyte is involved in such a manner that it enables conclusions to be drawn about the concentration of the analyte.

Detection reactions are understood in the present application as chemical and biochemical, in particular enzymatic reactions which involve the analyte to be determined and in the course of which the concentration of an indicator substance that is different from the analyte is changed in a manner which correlates with the concentration of the analyte. The indicator substance can be formed or converted in a single reaction in which the analyte directly participates or, on the other hand, the indicator substance, as in the case of a coagulation measurement, is only formed or converted in the course of a reaction cascade in which the analyte is involved at a different place. Correlation of the amount of converted indicator substance with the amount of analyte contained in the sample is preferably based on stoichiometric relationships. A calibration gives a relationship between the measured value for the indicator substance and the concentration of the analyte to be determined.
Thus glucose can for example be converted by glucose oxidase to gluconolactone and hydrogen peroxide in the presence of oxygen, the hydrogen peroxide reacting with a peroxidase in the presence of an indicator to form water and a coloured substance. In the present case this coloured substance corresponds to the indicator substance whose concentration can be determined photometrically or visually. Since the change in the concentration of this indicator substance correlates with the amount of analyte, the determination of this indicator substance can be used to deduce the amount of analyte that is present. Another example of such detection reactions and indicator substances is the enzymatic detection of triglycerides. In this case the sample liquid is firstly mixed with a reaction mixture which contains the substances necessary for the analyte determination in particular enzymes, coenzymes and substrates. The triglycerides are firstly converted by an esterase into glycerol which is in turn converted by a glycerokinase into glycerol-3-phosphate and subsequently by a glutathione peroxidase into dihydroxyacetone phosphate and hydrogen peroxide.
This is converted in the presence of a colourless indicator by peroxidase into water and a coloured substance which can be used as an indicator substance for determining the amount of triglycerides. Complex enzymatic detection reaction cascades are also often necessary to determine blood coagulation parameters such as thrombin or factor Xa. One example of a chemical detection reaction is the reaction of glycosylated haemoglobin (HbA1c) with a fluorescent boronic acid as a result of which the amount of free boronic acid decreases with increasing HbA1c concentrations in the sample in correlation with the amount of HbA1c.

In addition to determining the concentration of the analyte itself, the methods according to the invention can also be used to determine the rates of detection reactions and in particular of the conversions of the indicator substance.
These values can in turn be used to derive information about the concentrations and activities of the involved substances and in particular the involved enzymes.

An indicator substance in the sense of the present application refers to substances which generate a detectable signal which correlates with the amount or concentration of the analyte. Chromogenic or fluorescent substances can be used especially as indicator substances. Chromogenic substances can form a colour, lose their colour or change their colour. Fluorescent substances can generate fluorescence, lose their fluorescence or change their fluorescent properties. In particular such an indicator substance can be converted or formed by analyte-specific reactions. Other examples of indicator substances are acids or bases or redox equivalents which can be used especially for electrochemical detection methods.

According to the invention the detection reactions proceed in a first compartment, the reaction space, at least up to the formation or conversion of the indicator substance. In addition to the liquid sample, the reaction space contains substances and auxiliary agents necessary to carry out the detection reactions and in particular to form or convert the detection substance. In particular in the case of enzymatic detection reactions the enzymes, coenzymes, cofactors, substrates, buffer substances, indicators and mediators that are necessary for this are present in the reaction space or are released into the reaction space. This reagent mixture or parts of this mixture can be present in the form of a solution or suspension in an aqueous or non-aqueous liquid or be present as a powder or lyophilisate. In addition they can be present in the form of a dry chemistry test in which the reagent mixture is applied to a carrier. The carrier can for example be an absorbent or swellable material which is wetted by the sample liquid as a result of which the reagent mixture that is in or on this material in a dry form dissolves in the sample liquid and the detection reactions can take place.
The reagent mixture can also be applied to a carrier substrate in the form of soluble layers or films. The detection reactions can be started by contacting the sample liquid and reagent mixture directly in the reaction space or by adding a substance that is essential for the detection reactions at a later time. There are no limitations to the design of this reaction space and it can be adapted to the respective detection method by a person skilled in the field of instrument-based analytics. Thus for example the reaction space can be designed as the interior of a reaction vessel such as a cuvette or microtitre plate well. Especially in the case of a dry chemistry test strip the reaction space can also correspond to the volume of the liquid sample. If, for example, a drop of blood is applied to a test strip provided with detection reagents, it dissolves the reagent mixture which initiates the detection reactions. In this case the drop of liquid itself corresponds to the reaction space. Thus irrespective of its geometric shape, the reaction space is regarded as the volume in which the detection reactions take place at least up to the conversion or formation of the indicator substance.

According to the invention the indicator substance is not detected or determined in the reaction space itself but rather in a special second compartment, the extraction layer. This extraction layer is spatially separated from the reaction space but is in contact with this space in such a manner that liquids and substances dissolved therein that are at least below a certain exclusion size can pass from the reaction space into the extraction layer. According to the invention the extraction layer fulfils several functions:

- It enables the indicator substance to be detected in a specially suitable environment for this determination.

- It can be used to prevent substances that could interfere with the detection of the indicator substance from passing into the extraction layer so that the indicator substance can be detected substantially free of interference.

- It contains special substances, so-called capture substances, which selectively enrich the indicator substance in the extraction layer and thus increase the sensitivity and specificity of the analyte determination.

Hence one of the functions of the extraction layer is to enable the indicator substance to be determined as free of interference as possible. For this it is particularly necessary to create a spatially delimited area in which, on the one hand, the indicator substance is present at a concentration that can be readily detected and correlates with its concentration in the reaction space and in which, on the other hand, interfering substances cannot enter or only to a slight extent so that falsification of the determination of the indicator substance by these interfering substances is substantially avoided.

Substances which can interfere with a determination of the indicator substances are understood in the sense of the present application as all substances or particles which, when present together with the indicator substance in the liquid sample and/or the reagent mixture, impede or prevent a determination of the indicator substance with the respective detection method. Such substances can for example interact specifically or unspecifically with the indicator substance for example as a result of hydrophobic or ionic interactions and thus change the properties of the indicator substances that are utilized in the respective detection method. An example of this is a possible change in the fluorescence properties of indicator substances by interaction with other molecules or by a change in the microenvironment of the indicator substances by such interfering substances which are based on processes such as quenching or fluorescence resonance energy transfer or local changes in the pH. Other such interfering interactions can in particular also occur with proteins present in the sample and are described for example in the "Handbook of Fluorescent Probes and Research Products" (9th Edition, Molecular Probes Europe, Leiden, Netherlands).
However, interfering substances can also be substances or particles which, due to their properties, impede or prevent a determination of the indicator substance by at least partially masking the measurement signal of the indicator substance and thus falsify the result of the measurement. In particular chromogenic substances present in the reaction mixture can result in additional measurement signals in optical detection methods which are superimposed on the signal of the indicator substance such that it is no longer possible to differentiate between the measurement signal of the indicator substance and the effect of interfering substances which impedes or prevents a determination of the indicator substance. Such chromogenic substances can either be already originally present in the sample or only be formed during the course of the detection reactions. For example analyte determinations by optical detection methods can only be carried out and evaluated to a very limited extent in whole blood since haemoglobin which is present at high concentrations in whole blood absorbs strongly over a wide range of wavelengths and thus often completely masks a specific absorption of the indicator substance which is usually only present in small amounts. There are also similar problems in detection methods based on fluorescent indicator substances since their excitation and emission light is often also almost completely absorbed by the highly concentrated haemoglobin.

In electrochemical detection methods redox substances that interact with the indicator substance can for example also act as interfering substances.
According to the invention the extraction layer is spatially separated from the reaction space by designing the extraction layer as a special layer within the overall test system, said extraction layer being a diffusion barrier for certain substances such that substances selectively pass over from the reaction space into the reaction layer.
Selective in the sense of the present application does not necessarily mean a complete exclusion of certain substances from a layer or complete passage into a layer.
Selective also means that certain substances can selectively enter the layer and can accumulate there or can at least be partially kept out of the layer. Hence a selective exclusion of a substance by a layer does not necessarily mean the complete absence of this substance in the corresponding compartment but rather only a reduced concentration of this substance in the corresponding area since in practice it is not necessary to have a 100 % exclusion of substances.

The extraction layer is separated from the reaction space in particular due to the fact that the extraction layer is a matrix having a selective exclusion size for substances with a molecular weight of more than 1500 g/mol, preferably of more than 2000 g/mol and particularly preferably more than 15000 g/mol. Swellable and absorbent materials that can take up liquid come especially into consideration as such matrix materials. They can for example be corresponding fine-pored fibrous materials such as fleeces, fabrics, knitted fabrics or porous plastic materials. In particular such matrices can also be non-fibrous materials such as porous or non-porous films, membranes, gel matrices or polymer layers. In a particularly preferred embodiment the extraction layer is also in the form of a gel matrix in which the other components of the extraction layer and in particular the capture substances are incorporated. The gel matrix preferably has a layer thickness of less than 50 m, in particular of less than 5 m and is applied to a support such as an at least partially optically transparent support. The gel matrix is preferably a polymer which has a composition based on photopolymerizable monomers such as acrylic monomers e.g. acrylamide or/and acrylic acid esters e.g.
polyethylene glycol diacrylate or vinyl aromatic monomers e.g. 4-vinylbenzosulfonic acid, or combinations thereof.

In order to prepare such a gel matrix, a liquid which contains one or more photopolymerizable monomers, capture substances and optionally other additional components of the extraction layer such as colour pigments can, in a preferred embodiment, be applied to an at least partially optically transparent support such as a plastic foil and for example be irradiated with UV light from the rear to polymerize the monomers on the support to a predetermined layer thickness. The layer thickness can be controlled by adding absorbing substances to the reagent or/and by means of the duration or intensity of the irradiation. Excess liquid reagent can be removed after the polymerization and used again.

On the other hand the matrix can also be prepared by conventional coating procedures in which a suspension of all reagents required for the extraction layer is applied to a support where it is brought to the required thickness using suitable methods e.g. with a doctor knife and then dried or completely polymerized.

In addition to covalently cross-linked polymeric gel matrices, it is also possible to use non-covalently cross-linked gels as a component of the extraction layers for example polyelectrolyte gels e.g. alginate gels cross-linked with divalent ions.

It is also possible to use polyamide, polyvinylidene difluoride, polyethersulfone or polysulfone membranes as matrix materials. The other substances present in the extraction layer and in particular the capture substances can for example be incorporated into the membrane by impregnation. Furthermore, so-called open films can be used for the extraction layer such as those described in EP-B-0 016 387. For this purpose solids are added as fillers in the form of fine, insoluble, organic or inorganic particles to an aqueous dispersion of film-forming organic plastics and the other substances contained in the extraction layer and in particular capture substances are additionally added. Suitable film formers are preferably organic plastics such as polyvinyl esters, polyvinyl acetates, polyacrylic esters, polymethacrylic acid, polyacrylamides, polyamides, polystyrenes, mixed polymers of for example butadiene and styrene or of maleic acid ester and vinyl acetate or other film forming, natural and synthetic organic polymers as well as mixtures thereof in the form of aqueous dispersions. The dispersions can be spread on a support to form a uniform layer which results in a water-resistant film after drying. Although the other substances present in the extraction layer and in particular the capture substances are normally added to the dispersion used to prepare the open films, it may also be advantageous to impregnate the formed film with these reagents after its manufacture. It is also possible to pre-impregnate the fillers with the reagents.

The exclusion size of the matrix material can be adjusted in the above-mentioned cases in a manner known to a person skilled in the art by for example selecting suitable fillers and concentrations thereof, by controlling the degree of cross-linking of polymeric gel matrices or by a suitable concentration of cross-linking ions in polyelectrolyte gels and in particular be adapted to the interfering substances that are to be excluded.

The indicator substance can be determined in the extraction layer using a wide variety of detection methods known to a person skilled in the field of instrument-based analytics. In particular it is possible to use optical and electrochemical detection methods. Optical methods for example include the measurement of absorption, transmission, circular dichroism, optical rotation dispersion, refractometry or preferably fluorescence. Electrochemical methods can in particular be determinations of charge, potential or current. The test systems and methods according to the invention are particularly advantageous for optical methods which suffer particularly from light absorption by interfering substances, in particular blood components.

Immobilized capture substances are an essential component of the extraction layer.
Capture substances in the sense of the present application are understood as all substances that interact with the indicator substance and enable this substance to be selectively enriched in the extraction layer. A selective enrichment is understood as an enrichment of the indicator substance which results in a concentration of this substance in the extraction layer that is larger than the concentration that would arise as a result of a purely diffusive flow of this substance into the extraction layer. In particular the capture substance should selectively enrich the indicator substance in the sense that its concentration relative to the other components of the sample or of the reagent mixture is increased in the extraction layer. For this purpose the capture substances do not necessarily have to interact substance-specifically with the indicator substance as is for example the case for antigen-antibody interactions. The specificity can also encompass groups of substances that have common properties especially as a result of a similar chemical structure or similar physicochemical properties. For example all anionic indicator substances can in principle be enriched by cationic capture substances and conversely all cationic :indicator substances can be enriched by anionic capture substances. Hence capture substances can also have a limited specificity for the indicator substance based on a general interaction.

In particular substances that can specifically enrich indicator substances on the basis of hydrophilic or hydrophobic interactions can be used as capture substances.
For example cyclodextrins or sugar derivatives can be used as capture substances in order to selectively enrich carbohydrates or relatively hydrophobic indicator substances such as aminocoumarins, nitroanilines or phenylenediamines in the extraction layer on the basis of hydrophobic effects. Serum albumins can also be used.

Substances that can specifically enrich indicator substances on the basis of ionic interactions can also be used as capture substances. For example polyelectrolytes such as polycations or polysulfonic acids can be used as capture substances which, on the basis of electrostatic interactions, selectively enrich oppositely charged indicator substances in the extraction layer.

Furthermore substances that can specifically enrich indicator substances on the basis for complex-forming properties can be used as capture substances. For example chelators such as ethylenediamine tetraacetic acid derivatives can be used as capture substances to selectively enrich polyvalent ions in the extraction layer.

Moreover substances that can specifically enrich indicator substances on the basis of a precipitation reaction can be used as capture substances. For example anions or cations can be used specifically as capture substances for proteins in that a dissolved protein can be completely or partially deposited as a precipitate in the extraction layer by adding suitable salts.

Furthermore substances that can enrich indicator substances based on a specific interaction between the partners of a specific binding pair according to the key-lock principle can be used as capture substances. For example antibodies or antibody fragments can be used specifically as capture substances for special antigens or haptens. In addition proteins and especially enzymes can be used specifically as capture substances for corresponding cofactors in particular coenzymes, or, in an inactivated form, also for substrates of these enzymes. In addition nucleic acids and especially DNA or RNA can be used specifically as capture substances for corresponding nucleic acids which hybridize with these nucleic acids and in particular for complementary nucleic acids. Individual partners of other biological or chemical binding pairs such as biotin/streptavidin or biotin/avidin can also be used as capture substances.

According to the invention the capture substances must be present in an immobilized form in the extraction layer. Immobilization is understood in the sense of the present invention as all processes and measures which have the effect that the capture substances are retained in the extraction layer and cannot reach the reaction space.
This is the basis for a selective enrichment of the indicator substances in the extraction layer. In this connection the immobilization can be carried out in various ways. Methods for this are known to a person skilled in the art. It includes in particular the immobilization of the capture substances in the extraction layer. The immobilization can be in particular achieved by binding to a carrier substance which is preferably the matrix of the extraction layer. Binding to a carrier can preferably take place by adsorption, ion binding or covalent binding. Furthermore the immobilization can take place by enclosure in a layer in the form of gels, microcapsules or fibres through which the capture substances cannot pass. This immobilizing layer is preferably the matrix of the extraction layer.
Furthermore the immobilization can be achieved by cross-linking the capture substances within the extraction layer.

In addition to the capture substances, the extraction layer can contain other substances that can increase the detectability of the indicator substance in this layer.
For example coloured pigments can be added to the extraction layer in order to minimize interference by coloured layers behind it. This can be particularly advantageous in optical detection methods for determining analytes in whole blood in order to minimize the strong background colour of the haemoglobin. For this purpose pigments having a high refractive index can be added to the extraction layer.
Titanium dioxide can be preferably added in which case particles having an average diameter of about 0.2 to 0.8 m have proven to be particularly advantageous.

The concentration of the indicator substance in the extraction layer correlates with the concentration of the indicator substance in the reaction space. This concentration of the indicator substance in the reaction space in turn correlates with the concentration of the analyte in the reaction space from which the concentration of the analyte in the liquid sample can in turn be derived when the volume ratios of sample liquid and reaction mixture are known. Thus a determination of the indicator substance in the extraction layer allows a calculation of the concentration of the analyte in the liquid sample.

The determination of the indicator substance and thus the determination of the analyte can be carried out by a single determination of a measured value, in particular an end point determination or a measurement after a certain time interval or by a measurement over a certain time period in which discrete measured values are determined several times at discrete time intervals or by a measurement over a certain time period with continuous determination of the measured values.

The determination of the analyte or the indicator substance may be followed by other calculations which starting from the result of the analyte determination, yield other derived quantities which in turn can be used as diagnostic parameters. An example of this is the determination of parameters which can give diagnostic information about the presence of a coagulation disorder and are based on a determination of thrombin.
Thus for example the prothrombin value or Quick value as a parameter for coagulation disorders of the exogenous system can be ascertained from a determination of thrombin and in particular from the time course of thrombin values after adding thromboplastin and calcium to citrated blood. Furthermore the activated partial thromboplastin time as a parameter for coagulation disorders of the endogenous system can for example be ascertained from a determination of thrombin and in particular from the time course of thrombin values after adding platelet factor III to citrated blood. The activated clotting time is the time in which fresh blood clots in the presence of a contact activator and can for example be determined by determining thrombin and especially from the time course of thrombin values after adding sterile siliceous earth. The activated clotting time in combination with the thrombocyte count can be used to deduce the function of the endogenous coagulation system. Methods for calculating these parameters on the basis of thrombin determinations are known to a person skilled in the field of clinical diagnostics.

In addition to these methods the present invention also concerns a test system for determining analytes in a liquid sample which consists of at least two spatially separate compartments wherein the detection reactions, especially involving the indicator substance, necessary to determine the analyte in. the liquid sample are carried out in a first compartment, the reaction space, and the analytical determination of the indicator substance is carried out in a second compartment, the extraction layer. In order to increase the specificity and sensitivity, the extraction layer additionally contains, according to the invention, a capture substance in an immobilized form which selectively enriches the indicator substance. According to the invention these two compartments are spatially separated in such a manner that in particular passage of the indicator substance into the extraction layer is favoured but, on the other hand, substances which could interfere there with an analytical determination of the indicator substance are at least partially excluded from this layer.

Another subject matter of the invention is the use of a test system according to the invention to determine analytes in a liquid.

The above-mentioned aspects of the invention can be used either alone or in any combination.

The present invention is further elucidated by the following examples and figures.
Figure 1 shows time courses of mean values of the fluorescence intensity of aminomethylcoumarin in whole blood determined using the test carrier according to the invention for determining coagulation parameters as a function of the hydroxypropyl-beta-cyclodextrin concentration in the extraction layer.

Figure 2 shows time courses of mean values of the fluorescence intensity of aminomethylcoumarin determined using the test carrier according to the invention for determining coagulation parameters in whole blood of normal donors and Marcumar patients.

Example 1: Use of the method according to the invention to determine coagulation parameters by means of a fluorimetric thrombin determination The reaction principle of this thrombin determination is based on the following processes:

Coagulation of a blood sample is for example triggered by adding tissue factor as a result of which the coagulation cascade proceeds and finally prothrombin is converted into thrombin. Pefafluor TH (Pefa-15865; source: Pentapharm Ltd., Engelsgasse 109, CH-4002 Basle) is a specific substrate for thrombin and is proteolytically converted by thrombin with cleavage of aminomethylcoumarin.
The fluorescence properties of aminomethylcoumarin are considerably reduced in the substrate form by the amide binding to the tripeptide. The released aminomethyl-coumarin has a strong fluorescence at an excitation wavelength of 342 nm and an emission wavelength of 440 nm and hence it can be used to detect thrombin activity and thus to determine the amount or concentration of thrombin in the sample.
The thrombin concentration determined by the release of aminomethylcoumarin correlates with the course of the coagulation cascade. If the thrombin concentration is determined and recorded over a certain period which is usually several minutes after the start of the coagulation reaction, it is possible to determine other coagulation-specific parameters from the time course of the thrombin concentration such as prothrombin time, activated clotting time or activated partial thromboplastin time. These parameters are widely used to diagnose disorders of blood coagulation.

Example la: Thrombin determination in whole blood and plasma without extraction layers Firstly preliminary experiments were carried out which, in contrast to the method according to the invention, took place without an additional extraction layer.
For this Mowiol 4-88, Hepes buffer, sucrose, glycine, RPLA-4, Pefa-15865, tissue factor, polybrene and mega 8 were added to 5 l of a non-pretreated whole blood sample.
The concentrations of these substances are like those of the sprayed on coagulation mixture that is described in example Ic. A clearly visible clotting takes place but no fluorescence signal whatsoever can be detected in the blood. If plasma is used as the sample liquid instead of whole blood, it is possible to unambiguously observe the cleavage of aminomethylcoumarin by fluorescence measurements. This shows that the principle of determining thrombin by cleavage of the strongly fluorescent aminomethylcoumarin from Pefa-15865 can be used to determine coagulation parameters. Furthermore it was also shown that the simultaneous presence of haemoglobin or erythrocytes make it impossible to carry out such a determination in whole blood since haemoglobin almost completely quenches the fluorescence of aminomethylcoumarin dissolved in the blood. This fluorescence quenching did not occur due to the separation of blood cells and thus also the haemoglobin-containing erythrocytes as part of isolating plasma from whole blood but additional labour-intensive process steps such as centrifugation were necessary which makes the detection method more complex and more susceptible to interference.

Example 1b: Aminomethylcoumarin determination in extraction layers containing various capture substances A conventional layer structure with filter layers in front to remove interfering substances that is for example used to detect glucose in whole blood cannot be used to measure coagulation by fluorimetric determination of thrombin since the required coagulation factors in the blood of the patient have high molecular weights and would thus be at least partially held back by the layers. Similarly the phospholipids that are essential for coagulation and which are also very large cannot move in an unimpeded manner. Hence due to the exclusion criteria of the individual layers in conventional layer structures, an unimpeded coagulation reaction is no longer possible since especially macromolecular coagulation factors cannot pass unhindered into the reaction layer.

Therefore, according to the invention, test systems and methods were used which operated with the extraction layers described above in order to avoid the disadvantages of prior test systems. In this connection various formulations of extraction layers containing different capture substances that can specifically enrich aminomethylcoumarin in the extraction layer were knife--coated onto a poly-carbonate foil (Pokalon , 140 m thickness) which is transparent in the detection area and their fluorescence was measured optically together with blood to which aminomethylcoumarin had been added at a concentration of ca. 30 mg/1. For this purpose the extraction layer was irradiated from below through the transparent carrier with excitation light emitted by an LED. The excitation light excites aminomethylcoumarin to fluoresce and emit fluorescent light. This is measured in a detector after passing a suitable filter which is also located below the transparent carrier.

The basic formulation of the extraction layers have the following composition:
Substance Amount Function Mowiol 4-88 solution (20 % in 10 g Film former water PEG wetting agent solution 10 g Spreading the sample PEG wetting agent solution composed of:
PEG12000 40 g Geropon T77 solution (0.2 %) 200 g Transpafill 2.5 g Film opening TiO2 I g Pigment Various amounts of potential capture substances were then admixed with 20 g of this basic formulation. Firstly mixtures were prepared each containing 5 g polystyrene sulfonic acid, 5 g hydroxypropyl-beta-cyclodextrin or 5 g PEG 20000 per 20 g of the basic formulation and applied as described above to a po).ycarbonate foil.
Subsequently whole blood to which aminomethylcoumarin had been added was applied to the respective layers and the fluorescence of the aminomethylcoumarin was determined as described above. The use of an extraction layer containing PEG
20000 in this case only showed a very slight increase in fluorescence of about relative units within 60 sec after adding the blood sample to the test carrier. The use of an extraction layer containing polystyrenesulfonic acid. showed a considerable increase in the fluorescence intensity of about 2500 relative units within 60 sec after adding the blood sample to the test carrier. The use of an extraction layer containing hydroxypropyl-beta-cyclodextrin showed an even more pronounced increase in the fluorescence of more than 3000 relative units within 60 sec after adding the blood sample. Hence in the following experiments hydroxypropyl-beta-cyclodextrin was used as the capture substance. But it is also possible to use the other said substances as well as further substances as capture substances especially when the sensitivity of the detection is of secondary importance. An increase in the concentration of the aminomethylcoumarin capture substance hydroxypropyl-beta-cyclodextrin from 5 g to 7.5 g results in a further increase in the measured fluorescence. An additional increase to 10 g hydroxypropyl-beta-cyclodextrin only leads to a slight increase in the fluorescence intensity and hence a concentration of 7.5 g hydroxypropyl-beta-cyclo-dextrin per 20 g basic formulation was used in the subsequent experiments.

Example lc: Determination of the time course of coagulation by means of a fluorimetric determination of thrombin in whole blood On the basis of the preliminary experiments, a layer of 7.5 g hydroxypropyl-beta-cyclodextrin per 20 g basic formulation was applied to a test carrier in the aforementioned manner and sprayed with a coagulation reagent. A test carrier on which a layer was applied which only contained the basic formulation and no additional capture substances served as a control.

This coagulation reagent has the following composition:

Concentration Ingredient Manufacturer Id. No. Function 12.5 g/l Hepes Sigma 706574001 stabilizing the pH
23 g/l Glycine Roche 2012529-650 solubility, stability 55 g/l Sucrose Roche 2012391-650 solubility, stability 6.9 g/1 RPLA 4 new Roche protecting quality protein for TF
1 gll Mega 8 Roche 1813099001 wetting agent 0.0148 g/l Polybrene Roche 0435406-958 heparin (Aldrich) #1140300 neutralization 1.28 g/l Pefa-15865 Roche thrombin (1.9 mM) (M=675.79) substrate 218 g11 HrTF solution Dade-Behring 3147487001#11 activator (tissue factor) After spraying this reagent onto the coated foils the test carrier was dried (40 C, 10 min).
In order to determine the time course of coagulation, unstabilized blood was cooled in an ice bath until shortly before the start of the measurement and immediately heated to about 35 C before the measurement. The measurement took place on an unheated measurement block so that the temperature during the determination and the coagulation time course was at about room temperature. Since the coagulation reaction is an enzymatic reaction and is thus strongly temperature dependent, one would therefore expect from the start slower coagulation time courses compared to methods in which the sample is heated to 37 C. The device according to the invention can also be heated by an additional temperature control device which thus also allows more rapid coagulation measurements to be carried out. A person skilled in the field of analytical devices is familiar with such temperature control devices so that the sample liquid can be heated in a simple manner. The fluorescence was measured after adding the sample to the test carrier as previously described.

Fig. 1 shows two time courses for the measured fluorescence intensity after addition of whole blood at time t = 0 for such test carriers. The time t in seconds is plotted on the abscissa and the measured fluorescence intensity I at an excitation wavelength of 340 nm and an emission wavelength of 470 nm is plotted in relative units on the ordinate. In this case the upper curve 1 represents a curve of mean values of individual determinations using an extraction layer containing 7.5 g hydroxypropyl-beta-cyclodextrin per 20 g basic formulation and the lower curve 2 is a curve of mean values of 10 control determinations using an extraction layer which only contains the basic formulation and no specific capture substance. It can be clearly seen that the presence of hydroxypropyl-beta-cyclodextrin as a capture substance in the extraction layer can considerably increase the measured fluorescence intensity under otherwise identical test conditions. Thus with the aid of the method according to the invention it is in particular possible to utilize a larger measuring range of the measuring instrument resulting in more exact and sensitive measurements. This in turn increases the sensitivity and specificity of analytical methods that are based on such measurements.

Example id: Comparison of the time course of coagulation by means of a fluorimetric determination of thrombin in whole blood of normal donors and Marcumar patients Marcumar (Hoffmann-La Roche Aktiengesellschaft, Basle, Switzerland) is an orally administered coagulation inhibitor which delays but does not completely abolish blood coagulation. Marcumar inhibits the vitamin K-dependent synthesis of the coagulation factors II, VII, IX and X. Marcumar is primarily used for the prevention and treatment of venous thrombosis, myocardial infarctions and pulmonary embolisms. Since its action is associated with an elevated bleeding tendency, monitoring by regular control measurements is absolutely essential in order that the dosage can be adjusted if necessary. The monitoring is based on regular determinations of coagulation-specific parameters carried out by the doctor or the patients themselves. The method according to the invention can be preferably used for this purpose.

Fig. 2 shows two time courses of the measured fluorescence intensity after adding whole blood from normal donors and Marcumar patients at time t = 0. The time t in seconds is plotted on the abscissa and the measured fluorescence intensity I at an excitation wavelength of 340 nm and an emission wavelength of 470 nm is plotted in relative units on the ordinate. In both cases extraction layers containing 7.5 g hydroxypropyl-beta-cyclodextrin per 20 g basic formulation were used. The upper curve 1 represents a curve of mean values of 12 measurements using whole blood from normal donors as the sample liquid and the lower curve 2 is a curve of mean values of 12 control measurements using whole blood from Marcumarl' patients as the sample liquid. This clearly shows that the different time courses between normal donors and Marcumar patients can be recorded with the method according to the invention. Whereas with healthy normal donors a considerable increase in the fluorescence intensity from 550 relative units to about 4000 relative units after 360 seconds is observed about 60 seconds after sample application. In Marcumar patients there is firstly even a slight decrease in the measured fluorescence intensity and only after ca. 120 seconds is a slight increase in fluorescence intensity to ca. 1300 relative units after 360 seconds observed. This is due to the delayed coagulation caused by the Marcumar medication.

The principle of enzymatic cleavage of an indicator substance is independent of the cleaved species and the respective substrate. Other substrates, indicator substances and capture substances can also be used.

This example clearly shows that the method and test systems according to the invention enable a sensitive and specific determination of the concentration of an analyte in a complex sample mixture. Furthermore the method and test systems according to the invention enable the concentration of the analyte to be continuously determined over a certain time period or at discrete time intervals without interfering with the course of the detection reactions.

Example 2: Determination of glycosylated haemoglobin by means of fluorescently labelled boronic acids The principle according to the invention of determining analytes based on the determination of an indicator substance in a special extraction layer in which the indicator substance is enriched in the extraction layer by means of special capture substances and interfering substances remain exclusively in the extraction layer, can be applied to other analyte and parameters.

Another example is the determination of glycosylated haemoglobin (HbA1c) by means of fluorescently labelled boronic acids. HbA1c is a haemoglobin to which glucose is covalently bound. HbA1c also occurs in small amounts in the erythrocytes of healthy persons but occurs to an increasing extent in diabetics depending on the long-term blood sugar level. Hence HbA1c is especially suitable for retrospectively assessing the carbohydrate balance of these patients commensurate with the average lifespan of erythrocytes of 3 to 4 months and, as a long-term parameter, supplements the monitoring of blood sugar levels in addition to the short-term parameter blood glucose content. In this context the determination of HbA1c is of major diagnostic importance.

Fluorescently labelled boronic acids can be used especially as an indicator substance and special sugars and sugar derivatives, in particular diols, can be used as corresponding capture substances in the extraction layer.

One embodiment of a test carrier according to the invention for determining HbA1c in whole blood comprises a test carrier on which an extraction layer is applied which for example contains cis-diols, e.g. polysugars or polyalcohols, in an immobilized form as a specific capture substance. In addition a reagent mixture which contains at least one lysis reagent such as saponins and a certain amount of the fluorescently labelled boronic acid which is for example labelled with aminomethylcoumarin or pyrene trisulfonate is applied to the test carrier and preferably directly on the surface of the previously applied extraction layer. After applying the liquid sample, in this case whole blood, the reagent mixture is dissolved and the detection reaction is started in the reaction space which in this case corresponds to the volume of the liquid sample. In this process the boron group of the fluorescently labelled boronic acid binds covalently to the glucose units of HbAIc which is present in the liquid sample. The amount of fluorescently labelled boronic acid bound to haemoglobin correlates with the concentration of HbA1c in the sample. The more HbA1, is present in the sample, the more fluorescently labelled boronic acid is bound to haemoglobin and the lower is the concentration of free fluorescently labelled boronic acid in the reaction space. Since the free fluorescently labelled boronic acid serves as an indicator substance, this example shows that indicator substances do not necessarily have to be formed in the reaction space as part of the detection reactions but rather that a conversion of indicator substances that are already present can also be used for the analyte determination. The extraction layer has an exclusion size which does not allow haemoglobin to penetrate into it since haemoglobin would prevent the fluorimetric detection of the fluorescently labelled boronic acids. Hence the fluorescently labelled boronic acids bound to haemoglobin cannot penetrate into the detection layer. Instead the free fluorescently labelled boronic acids are used as indicator substances since these can enter the extraction layer due to their considerably smaller molecular size and, due to their specific properties, accumulate there due to their interaction with the special capture substances. The more HbA1c is present in the sample the less free fluorescently labelled boronic acid can enter the extraction layer and the smaller is the measured signal. The fluorescently labelled boronic acids are detected in the extraction layer with the aid of optical.
fluorescence methods. The diagnostic suitability of such a test system according to the invention can be further increased by designing it as a multiparameter test system.
Thus, for example, several different analytes which are known to exhibit a characteristic change in concentration or are generally absent or present when a certain clinical picture is present, can be determined in a common test system. The simultaneous measurement of several such related parameters enables the determination of different analytes at the same time and in a single operation which yields rapid diagnostic information. Furthermore, by taking into consideration specific combinations of the individual analytical results, it is often possible to obtain diagnostic information which would not be possible by only considering one parameter. Especially the specificity and/or sensitivity of the diagnostic method can be increased in this manner. In the present case a HbA1, determination can in particular be combined with the determination of the total haemoglobin content in the blood sample. These two measurements can subsequently be related to one another. In particular the HbAj proportion of the total haemoglobin content can be determined so that more exact diagnostic information is possible on the basis of this common approach.

Claims (21)

1. Method for determining a coagulation parameter in a sample of whole blood or a blood product derived therefrom, comprising:
a) providing a test system having at least two compartments, comprising a first compartment for a detection reaction required to determine said coagulation parameter, the detection reaction producing an indicator substance, and a second compartment for an analytical determination of the indicator substance, said first compartment being separated from said second compartment in a manner which allows the indicator substance to pass from the first compartment into the second compartment, while at least partially preventing passage of interfering components of the sample, which components can interfere with the analytical determination of the indicator substance in the second compartment; and a specific capture substance which selectively enriches the indicator substance in the second compartment, said specific capture substance being present in an immobilized form in the second compartment;
b) carrying out the detection reaction in said first compartment with conversion of a fluorescently labelled thrombin substrate to form a fluorescent indicator substance;
c) allowing the fluorescent indicator substance to pass into said second compartment and be enriched by said immobilized specific capture substance, without interfering components of the sample; and d) optically detecting the fluorescent indicator substance in the second compartment.
2. Method as claimed in claim 1, wherein said sample is of whole blood.
3. Method as claimed in claim 1, wherein said sample is of a blood product derived from whole blood selected from the group consisting of serum and plasma.
4. Method as claimed in any one of claims 1 to 3, wherein said coagulation parameter is selected from the group consisting of thrombin content and parameters derived therefrom.
5. Method as claimed in claim 4, wherein said coagulation parameter is selected from the group consisting of prothrombin time, activated clotting time and activated partial thromboplastin time.
6. Method as claimed in any one of claims 1 to 5, wherein said fluorescently labelled thrombin substrate is a substrate which is proteolytically converted by thrombin to form aminomethylcoumarin.
7. Method as claimed in any one of claims 1 to 6, wherein said specific capture substance is hydroxypropyl-beta-cyclodextrin or polyethylene glycol 20000.
8. Method for determining glycosylated haemoglobin in a sample of whole blood or a blood product derived therefrom, comprising:
a) providing a test system having at least two compartments, comprising a first compartment for a detection reaction required to determine said glycosylated haemoglobin, and a second compartment for an analytical determination of an indicator substance present in said first compartment, said first compartment being separated from said second compartment in a manner which allows the indicator substance to pass from the first compartment into the second compartment, while at least partially preventing passage of interfering components of the sample, which components can interfere with the analytical determination of the indicator substance in the second compartment;

and a specific capture substance which selectively enriches the indicator substance in the second compartment, said specific capture substance being present in an immobilized form in the second compartment;
b) specifically binding glycosylated haemoglobin with a low molecular weight labelled reagent in said detection reaction in said first compartment to produce glycosylated haemoglobin bound labelled reagent and unbound labelled reagent in said first compartment, said unbound labelled reagent being said indicator substance for said analytical determination in the second compartment;
c) allowing said unbound labelled reagent, as indicator substance, to pass into said second compartment and be enriched by said immobilized specific capture substance, while leaving interfering components of the sample and glycosylated haemoglobin bound labelled reagent in said first compartment; and d) optically detecting the indicator substance in the second compartment.
9. Method as claimed in claim 8, wherein the low molecular weight labelled reagent is a low molecular weight fluorescently labelled boronic acid.
10. Method as claimed in claim 8 or 9, wherein the specific capture substance is selected from the group consisting of carbohydrates and diols.
11. Method as claimed in any one of claims 1 to 10, wherein the selective enrichment of the indicator substance in the second compartment is based on a hydrophilic/hydrophobic interaction between the indicator substance and the specific capture substance.
12. Method as claimed in any one of claims 1 to 11, wherein said interfering components are blood cells and chromophoric substances.
13. Method as claimed in claim 12, wherein the chromophoric substance is haemoglobin.
14. Method as claimed in any one of claims 1 to 13, wherein said optically detecting in d) comprises fluorescent-optical detection.
15. Method as claimed in any one of claims 1 to 14, wherein the second compartment comprises a selectively permeable matrix.
16. Method as claimed in claim 15, wherein the selectively permeable matrix is a gel, film, membrane or polymer layer.
17. Method as claimed in claim 15 or 16, wherein the capture substance is immobilized in said selectively permeable matrix.
18. Method as claimed in any one of claims 1 to 14, wherein the second compartment comprises a matrix which immobilizes the capture substance and at the same time separates the second compartment from the first compartment.
19. Test system for determining a coagulation parameter in a sample of whole blood or a blood product derived therefrom, comprising at least two compartments comprising a first compartment for carrying out a detection reaction required to determine the coagulation parameter and a second compartment for an analytical determination of an indicator substance which participates in the detection reaction, wherein:
a) the first compartment and the second compartment are separated from one another in a manner which allows the indicator substance to pass from the first compartment into the second compartment, while at least partially preventing passage of interfering components of the sample, which components can interfere with the analytical determination of the indicator substance in the second compartment;
b) a specific capture substance immobilized in the second compartment, said specific capture substance selectively enriching the indicator substance in the second compartment; and c) the indicator substance is a fluorescent indicator substance formed in said first compartment by conversion of a fluorescently labelled thrombin substrate.
20. Test system for determining glycosylated haemoglobin in a sample of whole blood or a blood product derived therefrom, comprising at least two compartments comprising a first compartment for carrying out a detection reaction required to determine the glycosylated haemoglobin and a second compartment for an analytical determination of an indicator substance which participates in the detection reaction, wherein:
a) the first compartment and the second compartment are separated from one another in a manner which allows the indicator substance to pass from the first compartment into the second compartment, while at least partially preventing passage of interfering components of the sample, which components can interfere with the analytical determination of the indicator substance in the second compartment;
b) the indicator substance, in the first compartment, which participates in the detection reaction, is a low molecular weight labelled reagent which specifically binds to glycosylated haemoglobin in said first compartment to produce glycosylated haemoglobin bound labelled reagent and unbound labelled reagent in said first compartment, said unbound labelled reagent being said indicator substance for said analytical determination in the second compartment;
and c) a specific capture substance is immobilized in the second compartment to selectively enrich the indicator substance, from the first compartment, in the second compartment.
21. Test system according to claim 20, wherein the specific capture substance is based on a hydrophilic/hydrophobic interaction between the indicator substance and the specific capture substance.
CA2486043A 2003-10-31 2004-10-26 Method for determining an analyte by means of an extraction layer Expired - Fee Related CA2486043C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10350880.5 2003-10-31
DE10350880A DE10350880A1 (en) 2003-10-31 2003-10-31 Method for determining an analyte by means of an extraction layer

Publications (2)

Publication Number Publication Date
CA2486043A1 CA2486043A1 (en) 2005-04-30
CA2486043C true CA2486043C (en) 2011-04-05

Family

ID=34428537

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2486043A Expired - Fee Related CA2486043C (en) 2003-10-31 2004-10-26 Method for determining an analyte by means of an extraction layer

Country Status (5)

Country Link
US (1) US20050142032A1 (en)
EP (1) EP1531331B1 (en)
JP (1) JP4194992B2 (en)
CA (1) CA2486043C (en)
DE (1) DE10350880A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781172B2 (en) * 2003-11-21 2010-08-24 Kimberly-Clark Worldwide, Inc. Method for extending the dynamic detection range of assay devices
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
WO2006098804A2 (en) 2005-03-11 2006-09-21 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
WO2007102839A2 (en) * 2005-10-27 2007-09-13 Applera Corporation Optoelectronic separation of biomolecules
EP1813937A1 (en) * 2006-01-25 2007-08-01 Roche Diagnostics GmbH Electrochemical biosensor analysis system
US20090007947A1 (en) * 2006-12-22 2009-01-08 Angela Spangenberg Portable weather shielding canopy
US20100022916A1 (en) 2008-07-24 2010-01-28 Javanbakhsh Esfandiari Method and Apparatus for Collecting and Preparing Biological Samples for Testing
US8603835B2 (en) 2011-02-10 2013-12-10 Chembio Diagnostic Systems, Inc. Reduced step dual path immunoassay device and method
IN2015DN01404A (en) 2012-07-25 2015-07-03 Catalyst Biosciences Inc
EP3578635B1 (en) 2014-04-02 2021-11-03 Chembio Diagnostic Systems, Inc. Immunoassay utilizing trapping conjugate
CN110554007A (en) * 2014-04-30 2019-12-10 仪器实验室公司 Method and system for point-of-care coagulation assays by optical detection
US20160116466A1 (en) 2014-10-27 2016-04-28 Chembio Diagnostic Systems, Inc. Rapid Screening Assay for Qualitative Detection of Multiple Febrile Illnesses
ES2814123T3 (en) 2016-04-04 2021-03-26 Evonik Operations Gmbh Treatment of alkaline catalyzed alkoxylation products
WO2021016380A1 (en) * 2019-07-22 2021-01-28 Ortho-Clinical Diagnostics, Inc. Glycated hemoglobin measurement

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042335A (en) 1975-07-23 1977-08-16 Eastman Kodak Company Integral element for analysis of liquids
US4255384A (en) 1978-08-14 1981-03-10 Fuji Photo Film Co., Ltd. Multilayered integral element for the chemical analysis of the blood
DE2910134A1 (en) 1979-03-15 1980-09-25 Boehringer Mannheim Gmbh DIAGNOSTIC AGENT FOR DETECTING COMPONENTS OF BODY LIQUIDS
DE3029579C2 (en) 1980-08-05 1985-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Method and means for separating plasma or serum from whole blood
JPS57200862A (en) * 1981-06-05 1982-12-09 Fuji Photo Film Co Ltd Mutilayer analysis element utilizing unique binding reaction
US4522786A (en) * 1983-08-10 1985-06-11 E. I. Du Pont De Nemours And Company Multilayered test device for detecting analytes in liquid test samples
DE3516579A1 (en) * 1984-11-19 1986-05-22 Boehringer Mannheim Gmbh, 6800 Mannheim Coagulation test on test strips
JPS61245057A (en) 1985-04-23 1986-10-31 Fuji Photo Film Co Ltd Integral type multi-layered analyzing element
US4806311A (en) 1985-08-28 1989-02-21 Miles Inc. Multizone analytical element having labeled reagent concentration zone
EP0455225B1 (en) 1990-05-01 1995-03-29 Nacalai Tesque, Inc. Method for measuring the percentage of glycation of a particular protein
US5525475A (en) * 1992-08-12 1996-06-11 Ladouceur; Cynthia A. Diffusion through a membrane assaying apparatus and method
US5679548A (en) * 1993-02-02 1997-10-21 The Scripps Research Institute Methods for producing polypeptide metal binding sites and compositions thereof
US5416198A (en) * 1993-02-05 1995-05-16 Research Medical, Inc. Selective sorbent removal system using polycation activated substrates
US5695949A (en) * 1995-04-07 1997-12-09 Lxn Corp. Combined assay for current glucose level and intermediate or long-term glycemic control
WO1997029376A1 (en) * 1996-02-09 1997-08-14 Kalibrant Limited Assay apparatus
JP4070050B2 (en) 1998-07-24 2008-04-02 テルモ株式会社 Blood glucose level measuring method and apparatus
DE19843094A1 (en) * 1998-09-21 2000-03-23 Roche Diagnostics Gmbh Method for the determination of glycated hemoglobin
US7531362B2 (en) * 2001-06-07 2009-05-12 Medmira Inc. Rapid diagnostic assay
WO2004042364A2 (en) * 2002-11-05 2004-05-21 Therasense, Inc. Assay device, system and method
US20060210984A1 (en) * 2003-03-03 2006-09-21 Jeremy Lambert Use of nucleic acid mimics for internal reference and calibration in a flow cell microarray binding assay

Also Published As

Publication number Publication date
EP1531331A3 (en) 2006-11-02
CA2486043A1 (en) 2005-04-30
EP1531331A2 (en) 2005-05-18
EP1531331B1 (en) 2013-01-02
DE10350880A1 (en) 2005-06-02
US20050142032A1 (en) 2005-06-30
JP2005164580A (en) 2005-06-23
JP4194992B2 (en) 2008-12-10

Similar Documents

Publication Publication Date Title
US5418143A (en) Test article and method for performing blood coagulation assays
US5580744A (en) Test article and method for performing blood coagulation assays
US5135716A (en) Direct measurement of HDL cholesterol via dry chemistry strips
CA2486043C (en) Method for determining an analyte by means of an extraction layer
EP0654659B1 (en) Defined volume test device
US4994238A (en) Constant volume chemical analysis test device
RU2422835C2 (en) Whole blood thrombine activity test
US20030153084A1 (en) Control compositions and methods of use for coagulation tests
US20070077610A1 (en) Membrane system for blood coagulation testing
EP0716744B1 (en) Bioactive porous partition members
US20070077613A1 (en) Membrane system for blood coagulation testing
US20160245811A1 (en) Systems and methods for monitoring biological fluids
AU633210B2 (en) Asymmetric sandwich membrane system as diagnostic test device
EP0524596B1 (en) Method of measuring analyte using dry analytical element
JPH0726960B2 (en) Dry whole blood analysis element
JP2006521823A (en) Adhesive membranes that retain porosity and biological activity in assay devices for measuring serum cholesterol associated with high-density lipoproteins
JPH0526865A (en) Measuring method using dry process analysis element and dry process analysis element
US5118472A (en) Analytical element for analysis of whole blood
JPH0755810A (en) Device and method for detecting body under test
JPH05203655A (en) Device and method for biological analysis containing particle separation system
US5935802A (en) Method of assaying a blood sample for prothrombin
JPH02245199A (en) Measurement of one enzyme from mixture of isozyme and test carrier
JP3147560B2 (en) Multi-item analysis method
US20070082372A1 (en) Membrane system for blood coagulation testing
US20070077612A1 (en) Membrane system for blood coagulation testing

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181026